EOLS – evolus, inc. (US:NASDAQ)

DELAYED

^$ usd


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

1D

5D

1M

3M

YTD

1Y

3Y

1 Day EOLS SPY QQQ SPX

Date

Time

Symbol

Headline

Impact

Evolus (NASDAQ:EOLS) was given a new $17.00 price target on by analysts at Stifel Nicolaus.

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue [Yahoo! Finance]

Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Evolus sees Q4 net revenue between $88.6M and $90.6M [Seeking Alpha]

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Evolus (NASDAQ:EOLS) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 [Yahoo! Finance]

Evolus (NASDAQ:EOLS) was given a new $19.00 price target on by analysts at Mizuho.

Date

Time

Symbol

Company Name

Action

%Chg

Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.

Date

Time

Action

From

To

Firm

Impact

%Chg

details

Needham & Company LLC

Date

Time

Symbol

Headline

Impact

Form 8-K Evolus, Inc. For: Jan 09

Form 4 Evolus, Inc. For: Dec 22 Filed by: MOATAZEDI DAVID

Form 4 Evolus, Inc. For: Dec 22 Filed by: Avelar Rui

Form SCHEDULE 13G/A Evolus, Inc. Filed by: Nantahala Capital Management, LLC

Form SCHEDULE 13G/A Evolus, Inc. Filed by: Caligan Partners LP

Form SCHEDULE 13G/A Evolus, Inc. Filed by: LYNCH TIMOTHY P

Form 10-Q Evolus, Inc. For: Sep 30

Form 8-K Evolus, Inc. For: Nov 05

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size

Shares at ask / bid

Off exchange

Top News Gainers

6/4 Form 4/A Evolus, Inc. For: Jun 03 Filed by: Alphaeon Corp 16.7%

11/7 Evolus Announces Pricing of Public Offering of Common Stock 14.3%

7/17 Form 4 Evolus, Inc. For: Jul 15 Filed by: Parschauer Karah Herdman 11.6%

5/17 Form 424B4 Evolus, Inc. 8.0%

8/8 Juvly Aesthetics Continues Its Leadership Expansion with Appointment of a Chief People Officer 6.7%

2/25 Form 10-K Evolus, Inc. For: Dec 31 6.0%

5/21 ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt 5.4%

7/16 Form 8-K Evolus, Inc. For: Jul 15 4.8%

10/15 Evolus Inc (NASDAQ: EOLS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.4%

5/31 Form 4 Evolus, Inc. For: May 31 Filed by: SILVERNAIL LAUREN P 4.2%

Top News Decliners

5/15 ALPHAEON Corporation sells 4 million shares in Evolus Inc. -11.2%

8/13 Evolus Inc (NASDAQ: EOLS) had its "outperform" rating re-affirmed by analysts at JMP Securities. They now have a $30.00 price target on the stock. -11.0%

3/17 Form DEF 14A Evolus, Inc. For: May 01 -10.7%

2/25 Q4/2019 12/31/2019 EPS -0.470 ZacksConsensus -0.850 ActVsEst 0.380 - Beat -8.6%

3/27 Evolus Inc (NASDAQ: EOLS) had its price target lowered by analysts at HC Wainwright from $31.00 to $16.00. They now have a "buy" rating on the stock. -8.0%

3/4 Evolus Provides Update on International Trade Commission (ITC) Case -7.7%

1/9 Form 8-K Evolus, Inc. For: Jan 09 -7.0%

1/10 Form 8-K Evolus, Inc. For: Jan 10 -6.8%

3/3 Evolus to Participate in Barclays 2020 Global Healthcare Conference -6.3%

8/12 Q2/2019 6/30/2019 EPS -1.370 ZacksConsensus -0.960 ActVsEst (0.410) - Miss -6.2%

Don’t Miss Out On The Next BIG Stock Move

EOLS – evolus, inc. (US:NASDAQ)

DELAYED

^$ usd

1D

5D

1M

3M

YTD

1Y

3Y


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

EOLS

SPY

QQQ

SPX

EOLS – evolus, inc. (US:NASDAQ)

DELAYED

^$ usd

1D

5D

1M

3M

YTD

1Y

3Y


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

EOLS SPY QQQ SPX

Stock Stats

News Stats
Order Stats


All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings


Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size

Shares at ask / bid

Off exchange

Stock Stats

Order Stats


Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size

Shares at ask / bid

Off exchange

News Stats


All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

News

Evolus (NASDAQ:EOLS) was given a new $17.00 price target on by analysts at Stifel Nicolaus.

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue [Yahoo! Finance]

Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Evolus sees Q4 net revenue between $88.6M and $90.6M [Seeking Alpha]

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Evolus (NASDAQ:EOLS) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 [Yahoo! Finance]

Evolus (NASDAQ:EOLS) was given a new $19.00 price target on by analysts at Mizuho.

Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability [Yahoo! Finance]

5.4%

BEAT

-28.5%

MISS

-14.2%

MISS

-1.3%

MISS

Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.

Needham & Company LLC

Form 8-K Evolus, Inc. For: Jan 09

Form 4 Evolus, Inc. For: Dec 22 Filed by: MOATAZEDI DAVID

Form 4 Evolus, Inc. For: Dec 22 Filed by: Avelar Rui

Form SCHEDULE 13G/A Evolus, Inc. Filed by: Nantahala Capital Management, LLC

Form SCHEDULE 13G/A Evolus, Inc. Filed by: Caligan Partners LP

Form SCHEDULE 13G/A Evolus, Inc. Filed by: LYNCH TIMOTHY P

Form 10-Q Evolus, Inc. For: Sep 30

Form 8-K Evolus, Inc. For: Nov 05

Show more

Top News Gainers

6/4 Form 4/A Evolus, Inc. For: Jun 03 Filed by: Alphaeon Corp 16.7%

11/7 Evolus Announces Pricing of Public Offering of Common Stock 14.3%

7/17 Form 4 Evolus, Inc. For: Jul 15 Filed by: Parschauer Karah Herdman 11.6%

5/17 Form 424B4 Evolus, Inc. 8.0%

8/8 Juvly Aesthetics Continues Its Leadership Expansion with Appointment of a Chief People Officer 6.7%

2/25 Form 10-K Evolus, Inc. For: Dec 31 6.0%

5/21 ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt 5.4%

7/16 Form 8-K Evolus, Inc. For: Jul 15 4.8%

10/15 Evolus Inc (NASDAQ: EOLS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.4%

5/31 Form 4 Evolus, Inc. For: May 31 Filed by: SILVERNAIL LAUREN P 4.2%

Top News Decliners

5/15 ALPHAEON Corporation sells 4 million shares in Evolus Inc. -11.2%

8/13 Evolus Inc (NASDAQ: EOLS) had its "outperform" rating re-affirmed by analysts at JMP Securities. They now have a $30.00 price target on the stock. -11.0%

3/17 Form DEF 14A Evolus, Inc. For: May 01 -10.7%

2/25 Q4/2019 12/31/2019 EPS -0.470 ZacksConsensus -0.850 ActVsEst 0.380 - Beat -8.6%

3/27 Evolus Inc (NASDAQ: EOLS) had its price target lowered by analysts at HC Wainwright from $31.00 to $16.00. They now have a "buy" rating on the stock. -8.0%

3/4 Evolus Provides Update on International Trade Commission (ITC) Case -7.7%

1/9 Form 8-K Evolus, Inc. For: Jan 09 -7.0%

1/10 Form 8-K Evolus, Inc. For: Jan 10 -6.8%

3/3 Evolus to Participate in Barclays 2020 Global Healthcare Conference -6.3%

8/12 Q2/2019 6/30/2019 EPS -1.370 ZacksConsensus -0.960 ActVsEst (0.410) - Miss -6.2%